# 2025-08998: Pharmaceutical Company Seeks Approval to Import Controlled Medication

2025-08998, Importer of Controlled Substances Application: Quagen Pharmaceuticals LLC, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-05-20, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before June 20, 2025. Such persons may also file a written request for a hearing on the application on or before June 20, 2025. (as of 2026-10-22).

- Canonical: https://policyrisk.com/federal-register/2025-08998
- As of: 2026-10-22
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08998
- Title: Importer of Controlled Substances Application: Quagen Pharmaceuticals LLC
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 21510
- Published: 2025-05-20
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before June 20, 2025. Such persons may also file a written request for a hearing on the application on or before June 20, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-10-22

## In one line

Pharmaceutical Company Seeks Approval to Import Controlled Medication

## Summary

Quagen Pharmaceuticals LLC wants to become an official importer of certain controlled drugs, including Diphenoxylate. This means they’ll be allowed to bring these substances into the U.S. for medical or research use. If anyone has concerns or wants a hearing, they must speak up by June 20, 2025, so don’t miss the deadline!

## Abstract

Quagen Pharmaceuticals LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-21413](https://policyrisk.com/federal-register/2026-21413): Jefferson Burroughs, M.D.; Decision and Order, 2026-10-20
- [2026-21414](https://policyrisk.com/federal-register/2026-21414): Jan Pijanowski, M.D.; Decision and Order, 2026-10-20

## Sources
- [2025-08998 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/20/2025-08998/importer-of-controlled-substances-application-quagen-pharmaceuticals-llc)
- [2025-08998 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-20/pdf/2025-08998.pdf)

## Related
- [Previous: 2025-08997, Importer of Controlled Substances Application: Usona Institute](https://policyrisk.com/federal-register/2025-08997)
- [Next: 2025-08999, Open Meeting of the Taxpayer Advocacy Panel Taxpayer Communications Project Com…](https://policyrisk.com/federal-register/2025-08999)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08998 (as of 2026-10-22).
